Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1996-03-14
1998-06-02
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514965, 424400, A61K 31165
Patent
active
057600864
ABSTRACT:
The present invention is directed to a method for the prophylactic management of delayed emesis by the use of metoclopramide nasal spray.
REFERENCES:
patent: 4624965 (1986-11-01), Wenig
Clark et al., 1986, "Antiemetic (AE) trials to control delayed vomiting (V) following high-dose cisplatin (DDP)", Proceedings of ASCO 5:257, abstr. 1005.
Clark & Gralla, 1993, "Delayed emesis: A dilemma in antiemetic control", Support Care Cancer 1:182-185.
Cubeddu et al., 1993, "Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: Effects of antiemetics", J. Clin. Pharmacol. 33:691-697.
De Mulder et al., 1990, "Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting", Ann. of Internal Med. 113:834-840.
Du Bois et al., 1995, "Cisplatin-induced alterations of serotonin metabolism in patients with or without emesis following chemotherapy", Oncol. Rep. 2:839-842.
D.R. Gandara, 1991, "Progress in the control of acute and delayed emesis induced by cisplatin", Eur. J. Cancer 27:S9-S11.
Gandera et al., 1992, "The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo", Semin. Oncol. 19:67-71.
Grunberg et al., 1988, "Oral metoclopramide with or without diphenhydramine: Potential for prevention of late nausea and vomiting induced by cisplatin", J. of the Natl. Can. Inst. 80:864-868.
Jones et al., 1991, "Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy", Lancet 338:483-486.
Kris et al., 1989, "Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin", J. of Clin. Oncol. 7:108-114.
Kris et al., 1992, "Oral ondansetron for the control of delayed emesis after cisplatin", Cancer Suppl. 70:1012-1016.
Lee et al., 1994, "Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis", J. of Korean Med. Sci. 9:369-375.
Levitt et al., 1993, "Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil", New England J. of Med. 328:1081-1084.
Li et al., 1991, "Control of cisplatin-induced delayed emesis", Chin. Med. J. (Taipei) 48:451-455.
Madej et al., 1994, "A report comparing the use of tropisetron (Navoban), a 5-HT.sub.3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis", Semin. Oncol. 21:3-6.
Moreno et al., 1992, "Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients", Eur. J. Cancer 28:1344-1347.
Navari et al., 1995, "Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo", J. of Clin. Oncol. 13:2408-2416.
Nino et al., 1987, "A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine", Jpn. J. Cancer Chemotgher. 14:2881-2884.
O'Brien et al., 1989, "The role of metoclopramide in acute and delayed chemotherapy induced emesis: A randomized double blind trial", Br. J. Cancer 60:759-763.
G.S. Ogawa, 1982, "Metoclopramide as an antiemetic in chemotherapy", New Eng. J. of Med. Correspond. 307:249-250.
Roila et al., 1991, "Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone", Am. J. Clin. Oncol. (CCT) 14:238-242.
Scaglione et al., 1993, "Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients", Arzneim.-Forsch.Drug Res. 43:986-988.
Soukop et al., 1992, "Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer", Oncol. 49:295-304.
strum et al., 1985, "Management of cisplatin(DDP)-induced delayed-onset nausea(N) and vomiting(V): Preliminary results with 2 drug regimens", Proceedings of ASCO 4:263, abstr. C-1024.
M.C. Locatelli et al., Mar. 14, 1995, "Tolerability and Safety of Nasally Administered Metoclopramide (MCP) for the Prevention of CIS-Platinum (CDDP) Induced Delayed Emesis", Proceedings of ASCO vol. 14 Mar. 1995, abstr. 1759.
Chiara et al., 1995, "Prevention of Delayed Emesis with Metoclopramide and Dexamethasone in Patients Receiving Moderately Emetogenic Cytotoxic Treatment," Anticancer Research 15:1597-1599.
Tomirotti et al., 1994, "Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients," Support Care Cancer 2:389-392.
Roila et al., 1994, "Cisplatin-induced delayed emesis: Pattern and prognostic factors during three subsequent cycles," Annals of Oncology 5:585-589.
Reamer James H.
RiboGene, Inc.
LandOfFree
Nasal administration of agents for treatment of delayed onset em does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nasal administration of agents for treatment of delayed onset em, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nasal administration of agents for treatment of delayed onset em will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1460370